injection site pain tirzepatide Reaction Treatment: Evidence-Based Management Guide How & Where to Inject

Presented for research literature review only Herrington WG et al

Through paracrine signals or direct contact, these immune subpopulations precisely regulate the regeneration process

Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data

CPG is pivoting across the aisles from chicken bowls to snack chips to supplements